Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

ENTA has not yet commented on when it will report data from the Zelicapavir PSVHR trial (for high-risk adults) because that depends on whether enrollment is completed during the current RSV season in the Northern Hemisphere.

ENTA mentioned that they will have to go to the southern hemisphere for the RSVHR study so enrollment won't be completed for this study in the 2024 northern hemisphere season, but could still be completed this calendar year after the southern hemisphere season
I don't recall if ENTA had as much detail on the CSU program, but they did mention during the last presentation they have been working on it for a long time (over a year), so I am hoping they are not too far behind THRD (which incidentally has a higher valuation w their CSU program being the lone asset and cash through 2026 vs 2027 for ENTA)